All News

Investigators are evaluating a variety of medications for the novel coronavirus disease 2019 (COVID- 19), and the possible treatment landscape is rapidly evolving.

In the face of COVID-19, pharmacists continue to provide accessible care to patients.

Never before have so many brilliant minds, machines, and groups come together so quickly in an attempt to develop a vaccine.

Nearly 94% of survey respondents agreed that provider status is important for the future of pharmacy.

In July 2019, the FDA approved darolutamide (Nubeqa, Bayer) for men with prostate cancer that has not spread (ie, nonmetastatic) and no longer responds to medical or surgical treatment that lowers testosterone (ie androgen deprivation therapy).

Officials with the FDA granted Emergency Use Authorization (EUA) to the first diagnostic test that will allow at-home collection of saliva samples for coronavirus disease 2019 (COVID-19) testing.

The letter to congressional leaders warned that without reform, vulnerable populations could lose access to pharmacies, which are the first point-of-care for many.

Hydroxychloroquine has been widely used for treatment of COVID-19, despite the lack of strong evidence supporting its efficacy.

Here's a roundup of the latest coronavirus-related news.

In August 2019, the FDA approved entrectinib for treatment of adult patients with metastatic non-small cell lung cancer that is ROS1-positive.

Apremilast (Otezla, Amgen) significantly improved psoriasis symptoms compared with a placebo in adults with mild-to-moderate disease.

The FDA recently added famotidine to its list of drug shortages.

Today, the American Society of Health-System Pharmacists (ASHP) sent a letter to Vice President Mike Pence to urge the transparent and orderly allocation of remdesivir among hospitals

A new study suggests that well-controlled blood sugar may reduce mortality for patients with diabetes and COVID-19.

Officials with the FDA have approved celecoxib oral solution 25 mg/mL (Elyxyb, Dr. Reddy’s Laboratories) for the acute treatment of migraine with or without aura in adults.

Capmatinib (Tabrecta, Novartis) is a kinase inhibitor effective in blocking a key enzyme, resulting in decelerated tumor cell growth.

Results of the study showed that antihypertensive medications do not put individuals at increased risk for COVID-19.

The National Association of Specialty Pharmacy has announced that former interim chair of the Democratic National Committee Donna Brazile and former chairman of the Republican National Committee Michael Steele will give a joint keynote presentation on the political landscape, election 2020, and the future of their respective parties.

Roche received FDA Emergency Use Authorization for its anti-SARS-CoV-2 antibody test, Elecsys.

Devin English, assistant professor at Rutgers School of Health, joined Drug Topics® to discuss how COVID-19 is disproportionately affecting minorities, the history that explains this trend, and the issues that will remain after the pandemic ends.

The free online tool aims to help individuals find alternative drug options for medications in shortage.

Rituximab-abbs (Truxima) is the only biosimilar to the reference product rituximab (Rituxan). 

The study warned that, with 74 million children in the United States, PICU resources could face concerning strain from COVID-19.

A new study evaluated methods of improving heart function in individuals with type 2 diabetes.

A case report from NYU Langone Health assessed the use of both urgent and non-urgent telemedicine visits.

Officials with the FDA have issued an emergency use authorization for remdesivir (Gilead Sciences) for the treatment of suspected or laboratory-confirmed coronavirus disease 2019 (COVID-19) in hospitalized adults and children. 

Here's a roundup of this week's coronavirus-related news.

In part 2 of our interview, Aman Brar, chief executive officer of Jobvite, discussed with Drug Topics® how recruiting software is transforming the hiring process during the coronavirus disease 2019 pandemic.

In-depth interviews from 59 women living with HIV revealed that many women preferred long-acting injectable antiretroviral therapy for its convenience, privacy, and perceived effectiveness.

Officials with the FDA approved niraparib (Zejula, GlaxoSmithKline), a once-daily, oral monotherapy, for the first-line maintenance treatment of platinum-responsive advanced ovarian cancer regardless of biomarker status.